BJERKHOLT ERIC
CHIEF FINANCIAL OFFICER
5 filings on record here, covering MIRM, SMG, LRCX. Amounts are the ranges the filer reported, which is how the law requires them to be disclosed.
Filings
CORPORATEFiled 2026-08-12
| Sell | MIRM | Mirum Pharmaceuticals, Inc. | $599,510 |
CORPORATEFiled 2026-08-05
| Other | SMG | SCOTTS MIRACLE-GRO CO | $5,000 |
CORPORATEFiled 2026-07-06
| Other | SMG | SCOTTS MIRACLE-GRO CO | $5,000 |
| Award | SMG | SCOTTS MIRACLE-GRO CO | |
CORPORATEFiled 2026-06-15
| Sell | LRCX | LAM RESEARCH CORP | $106,713 |
| Sell | LRCX | LAM RESEARCH CORP | $497,635 |
| Sell | LRCX | LAM RESEARCH CORP | $393,778 |
| Sell | LRCX | LAM RESEARCH CORP | $1,374,558 |
| Sell | LRCX | LAM RESEARCH CORP | $686,446 |
| Sell | LRCX | LAM RESEARCH CORP | $295,831 |
| Sell | LRCX | LAM RESEARCH CORP | $981,379 |
| Sell | LRCX | LAM RESEARCH CORP | $852,009 |
| Sell | LRCX | LAM RESEARCH CORP | $838,143 |
| Sell | LRCX | LAM RESEARCH CORP | $438,192 |
| Sell | LRCX | LAM RESEARCH CORP | $2,129,759 |
| Sell | LRCX | LAM RESEARCH CORP | $1,483,161 |
| Sell | LRCX | LAM RESEARCH CORP | $1,549,734 |
| Sell | LRCX | LAM RESEARCH CORP | $1,865,050 |
CORPORATEFiled 2026-06-15
| Sell | LRCX | LAM RESEARCH CORP | $328,783 |
| Sell | LRCX | LAM RESEARCH CORP | $366,725 |
| Sell | LRCX | LAM RESEARCH CORP | $643,826 |
| Sell | LRCX | LAM RESEARCH CORP | $435,048 |
| Sell | LRCX | LAM RESEARCH CORP | $365,737 |
| Sell | LRCX | LAM RESEARCH CORP | $1,249,564 |
| Sell | LRCX | LAM RESEARCH CORP | $509,405 |
| Sell | LRCX | LAM RESEARCH CORP | $1,106,503 |
| Sell | LRCX | LAM RESEARCH CORP | $979,419 |
| Sell | LRCX | LAM RESEARCH CORP | $1,193,651 |
| Sell | LRCX | LAM RESEARCH CORP | $2,293,093 |
| Sell | LRCX | LAM RESEARCH CORP | $1,511,396 |
| Sell | LRCX | LAM RESEARCH CORP | $530,631 |
| Sell | LRCX | LAM RESEARCH CORP | $12,628 |
Source records are public filings: House and Senate periodic
transaction reports, Office of Government Ethics filings, and SEC Form 4 filings. Amounts
are reported as ranges by law, not exact figures, and filings arrive on a legal delay.
Eltrove reports what was filed. Nothing here is investment advice or a recommendation.